Compare TIPT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIPT | IRWD |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.2M | 741.8M |
| IPO Year | 2017 | 2009 |
| Metric | TIPT | IRWD |
|---|---|---|
| Price | $16.22 | $3.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | 201.9K | ★ 2.8M |
| Earning Date | 06-09-2026 | 05-26-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 0.76 | 0.15 |
| Revenue | $488,000.00 | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | $25.00 | ★ $23.17 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $15.94 | $0.55 |
| 52 Week High | $27.38 | $5.78 |
| Indicator | TIPT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 42.28 |
| Support Level | N/A | $3.08 |
| Resistance Level | $18.39 | $3.93 |
| Average True Range (ATR) | 0.53 | 0.33 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 15.74 | 36.97 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.